Streetbeat News

Products Services

AFIB

Acutus Medical has received a European patent (EP3294399) for a catheter system designed for left heart access, marking a significant milestone in the company's innovation trajectory.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:56 pm

SONY

Helldivers 2, funded by Sony Group Corp. (NYSE:SONY), reached 409,337 concurrent players on Steam, making it the fifth most popular game despite its $40 price tag. The game, released on Feb. 8, faced server issues due to high demand but saw improvements. CEO Johan Pilestedt advised players to wait until server capacity improves for a better experience. The game's success is notable, especially with its higher price compared to the top paid title, Palworld.

Portfolio Pulse from Franca Quarneti

February 20, 2024 | 8:50 pm

CANE

The Teucrium Sugar Fund ETF (NYSE:CANE) is experiencing a downtrend since Feb. 12, amidst expectations of a 20% increase in raw sugar prices by 2024 due to a global supply glut influenced by stable production in Brazil and stagnant growth in India. Despite the downtrend, CANE offers a unique investment opportunity as it tracks sugar futures, a commodity not moving in tandem with U.S. stock market trends, potentially serving as a market hedge. The ETF showed signs of a potential reversal with a dragonfly doji candlestick indicating a possible local bottom.

Portfolio Pulse from Melanie Schaffer

February 20, 2024 | 8:42 pm

COIN

HOOD

Retail investors are cautiously returning to the cryptocurrency market, with significant increases in activity reported by major U.S. crypto exchanges like Coinbase and Robinhood. Despite the market's volatility and the losses faced during the 2022 crash, the launch of U.S. ETFs investing in Bitcoin has reignited interest. However, the current level of enthusiasm does not match the previous bull market's fervor. Retail traders, crucial to the crypto ecosystem, are adopting a more measured approach, emphasizing risk management and the potential for long-term growth.

Portfolio Pulse from Murtuza Merchant

February 20, 2024 | 8:38 pm

AVGR

Avinger, Inc. has been granted a new U.S. patent (#11903677) for its innovations in occlusion-crossing devices, imaging, and atherectomy devices. This patent strengthens Avinger's intellectual property portfolio, potentially enhancing its competitive position in the medical device market.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:32 pm

MSTR

Michael Saylor, executive chairman of MicroStrategy Inc (NASDAQ:MSTR), remains bullish on Bitcoin, emphasizing a long-term 'buy and hold' strategy. He views ETFs as a gateway for institutional capital into Bitcoin, predicting this will benefit the Bitcoin ecosystem and MicroStrategy's leveraged strategy. Saylor sees Bitcoin as the ultimate exit strategy and a superior store of value, predicting capital will shift from traditional assets to Bitcoin.

Portfolio Pulse from Murtuza Merchant

February 20, 2024 | 8:16 pm

DIS

FOX

FUBO

WBD

FuboTV has initiated legal action to prevent ESPN, Warner, and Fox Sports from launching a joint streaming service, as reported by the Wall Street Journal.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:03 pm

VRTX

Vertex Pharmaceuticals (NASDAQ: VRTX) has received diverse analyst ratings over the last three months, with a shift towards more bullish sentiments in recent evaluations. The average 12-month price target for VRTX has increased to $438.1, up 5.86% from the previous target. Analysts from firms like Cantor Fitzgerald, JP Morgan, and Goldman Sachs have adjusted their price targets and ratings, reflecting optimism about Vertex's market performance and its portfolio of treatments for diseases like cystic fibrosis and beta thalassemia.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 8:00 pm

SPRY

ARS Pharmaceuticals Inc (NASDAQ:SPRY) released topline results from a clinical study for its EpiPen alternative, neffy, showing positive outcomes compared to epinephrine intramuscular injections. The data will be submitted to the FDA in Q2 2024 as a response to a previous rejection. The study demonstrated that repeat doses of neffy, whether in the same or opposite nostrils, resulted in higher pharmacodynamic responses than injections, indicating its efficacy in reversing anaphylaxis symptoms. Following these results, William Blair upgraded ARS Pharmaceuticals to Outperform.

Portfolio Pulse from Vandana Singh

February 20, 2024 | 7:53 pm

CISO

CISO Global's shares surged following the announcement that its initial suite of IP solutions has been valued at over $50 million.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:51 pm